Section 2 of the Crime (Sentences) Act 1997 (the 1997 Act) introduced a mandatory life sentence for a second serious offence, meaning judges had to impose a life sentence on anyone convicted of a second specified serious offence, unless there were exceptional circumstances.<\/p>
<\/p>
Although the \u2018two-strike\u2019 life sentence and the IPP sentence can be imposed for similar specified offences, unlike the IPP sentence, the \u2018two-strike\u2019 life sentence is a life sentence, and offenders will therefore be subject to licence conditions for life if they are released by the Parole Board. The recent changes to the IPP licence, which can be terminated pursuant to section 31A of the 1997 Act, would therefore not align with this life licence.<\/p>
<\/p>
We will be launching a review of the sentencing framework. The details of this review will be announced in due course.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/5364", "label" : {"_value" : "Biography information for Lord Timpson"} } , "answeringMemberPrinted" : {"_value" : "Lord Timpson"} , "dateOfAnswer" : {"_value" : "2024-07-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-07-29T10:03:46.497Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "54"} , "answeringDeptShortName" : {"_value" : "Justice"} , "answeringDeptSortName" : {"_value" : "Justice"} , "date" : {"_value" : "2024-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prison Sentences"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what plans they have to review the cases of those still subject to the \"two strikes\u201d sentence imposed under the Powers of Criminal Courts (Sentencing) Act 2000 or the \u201cautomatic life\" sentence introduced in 2012; and whether there is scope to align their licence conditions with those imposed through the Victims and Prisoners Act 2024 on prisoners serving an indeterminate sentence for public protection.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4883", "label" : {"_value" : "Biography information for Lord Moylan"} } , "tablingMemberPrinted" : [{"_value" : "Lord Moylan"} ], "uin" : "HL68"} , {"_about" : "http://data.parliament.uk/resources/1668176", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1668176/answer", "answerText" : {"_value" : "
It is not usual practice to ring-fence research funds for particular topics or conditions. As with other Government funders of health research, the National Institute for Health and Care Research (NIHR) does not allocate funding for specific disease areas. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.<\/p>
<\/p>
The Department welcomes the APPG report, recommendations of which continue to be worked through with the Department of Science, Innovation and Technology, and UK Research and Innovation and the Medical Research Council (MRC), and with the NIHR.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2023-11-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-11-13T17:49:10.747Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-11-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Brain: Tumours"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government, further to the All-Party Parliamentary Group on Brain Tumours report Brain Tumours: Pathway to a Cure \u2014 breaking down the barriers, published on 28 February, whether they have accepted recommendation six contained in that report that specific funding should be ring-fenced for research into childhood brain tumours; and if so, what is the timescale for implementation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4230", "label" : {"_value" : "Biography information for Baroness Randerson"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Randerson"} ], "uin" : "HL68"} , {"_about" : "http://data.parliament.uk/resources/1461041", "AnsweringBody" : [{"_value" : "Cabinet Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1461041/answer", "answerText" : {"_value" : "
Following consideration by the Office of the Parliamentary Counsel, the Government has today issued a written ministerial statement setting out its approach to the use of gendered language in legislative drafting.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4200", "label" : {"_value" : "Biography information for Lord True"} } , "answeringMemberPrinted" : {"_value" : "Lord True"} , "dateOfAnswer" : {"_value" : "2022-05-23", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL67"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-05-23T16:42:17.09Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "53"} , "answeringDeptShortName" : {"_value" : "Cabinet Office"} , "answeringDeptSortName" : {"_value" : "Cabinet Office"} , "date" : {"_value" : "2022-05-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Legislative Drafting"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what consultation they have undertaken in advance of the development of proposals regarding the review of language used in drafting legislation, following the passage of the Ministerial and other Maternity Allowances Act 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2024", "label" : {"_value" : "Biography information for Lord Hunt of Kings Heath"} } , "tablingMemberPrinted" : [{"_value" : "Lord Hunt of Kings Heath"} ], "uin" : "HL68"} , {"_about" : "http://data.parliament.uk/resources/1313676", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1313676/answer", "answerText" : {"_value" : "
The Joint Committee on Vaccination and Immunisation (JCVI) is supported by 4.5 full time positions as secretariat to the committee. The secretariat are based in the Immunisation Division in the National Infection Service of Public Health England (PHE) and managed by the Head of Immunisation in PHE.<\/p>
<\/p>
The secretariat gathers information from a range of sources, including from academic research, PHE and from industry sources. Decisions on information to be shared with the JCVI are made by the secretariat in consultation with consultant epidemiologists, the Head of Immunisation and the Chair of the Committee. Members may also share information with the secretariat or the JCVI. The secretariat are educated to degree level or higher in biological sciences disciplines and are supported by the Head of Immunisation in PHE and a number of consultant epidemiologists and scientists.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4708", "label" : {"_value" : "Biography information for Lord Bethell"} } , "answeringMemberPrinted" : {"_value" : "Lord Bethell"} , "dateOfAnswer" : {"_value" : "2021-05-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL69"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-05-20T14:18:27.567Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Joint Committee on Vaccination and Immunisation"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government how many civil servants at the Department of Health and Social Care support the work of the Joint Committee on Joint Committee on Vaccination and Immunisation (JCVI); which teams those staff are in; who they are managed by; and how they filter information they provide to the JCVI.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4286", "label" : {"_value" : "Biography information for Lord Mendelsohn"} } , "tablingMemberPrinted" : [{"_value" : "Lord Mendelsohn"} ], "uin" : "HL68"} , {"_about" : "http://data.parliament.uk/resources/1168610", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1168610/answer", "answerText" : {"_value" : "
The agreement we have reached with the European Union is that until 31 December 2020 there will be no changes to reciprocal healthcare access for pensioners, workers, students, tourists and other visitors, the European Health Insurance Card scheme, or planned treatment.<\/p>
<\/p>
People who have settled in the EU or United Kingdom before 31 December 2020, will continue to have life-long reciprocal healthcare rights provided they remain covered under the terms of the Withdrawal Agreement. This means existing healthcare arrangements will not change for those UK nationals who are resident in the EU and EU citizens in the UK before 31 December 2020, for as long as they are living in that country and covered by the agreement.<\/p>
<\/p>
We want to continue discussing the future of reciprocal healthcare arrangements with the EU as part of the future relationship discussions.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2020-01-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-01-07T12:41:45.027Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-12-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Health Services: British Nationals Abroad"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what steps they are taking, if any, to ensure continued access for British citizens to health services in the EU after Brexit, including continued access to the benefits of the European Health Insurance Card.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/518", "label" : {"_value" : "Biography information for Baroness Quin"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Quin"} ], "uin" : "HL68"} , {"_about" : "http://data.parliament.uk/resources/1149775", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1149775/answer", "answerText" : {"_value" : "
To extend the indication of Avastin, the Marketing Authorisation Holder (Roche Registration GmbH) would need to submit the results of relevant clinical trials and other information to the European Medicines Agency (EMA) to demonstrate acceptable safety and efficacy and a positive balance of benefit to risk. At present, as Avastin has a European Community Marketing Authorisation, a national submission to the Medicines and Healthcare products Regulatory Agency to extend the indication is not possible.<\/p>
There has not been any recent positive opinion from the EMA for a new indication of Avastin to be submitted to the European Commission and the EMA has not published any pending extension of indication applications.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-10-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-25T12:11:29.293Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Bevacizumab"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether there are (1) current applications, or (2) pending requests, for the use of Avastin following Phase 3 clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL68"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 6, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }